Third harmonic bio inc THRD.US Overview Analysis
THRD AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
THRD Current Performance
0.19%
Third harmonic bio inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to THRD
- VNDA Vanda pharmaceuticals inc.Value 4Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
THRD Profile
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.